Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE β0-THALASSEMIA

Trial Profile

A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE β0-THALASSEMIA

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glutamine (Primary)
  • Indications Beta-thalassaemia; Sickle cell anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Emmaus Medical
  • Most Recent Events

    • 13 Jul 2023 According to an Emmaus Life Sciences, Inc media release, the company has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.
    • 14 Dec 2021 According to an Emmaus medical media release, post hoc analysis from this study were presented at the 63rd American Society of Hematology Annual Meeting & Exhibition
    • 14 Dec 2021 Results of post hoc analysis from this study presented in an Emmaus medical media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top